NO20020365L - Oligonukleotider for inhibiering av ekspresjonen av humant eg5 - Google Patents

Oligonukleotider for inhibiering av ekspresjonen av humant eg5

Info

Publication number: NO20020365L
Authority: NO; Norway
Prior art keywords: oligonucleotides; inhibiting; expression; human
Prior art date: 1999-07-28

Application number

NO20020365A

Other languages

English (en)

Other versions

NO20020365D0 (no

Inventor

Eugen Uhlmann

Beate Greiner

Eberhard Unger

Gislinde Gothe

Marc Schwerdel

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-28

Filing date

2002-01-23

Publication date

2002-03-25

2002-01-23 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2002-01-23 Publication of NO20020365D0 publication Critical patent/NO20020365D0/no

2002-03-25 Publication of NO20020365L publication Critical patent/NO20020365L/no

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20020365A 1999-07-28 2002-01-23 Oligonukleotider for inhibiering av ekspresjonen av humant eg5 NO20020365L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19935303A DE19935303A1 (de)	1999-07-28	1999-07-28	Oligonukleotide zur Inhibierung der Expression von humanem eg5
PCT/EP2000/007345 WO2001007602A2 (de)	1999-07-28	2000-07-21	Oligonukleotide zur inhibierung der expression von humanem eg5

Publications (2)

Publication Number	Publication Date
NO20020365D0 NO20020365D0 (no)	2002-01-23
NO20020365L true NO20020365L (no)	2002-03-25

Family

ID=7916259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20020365A NO20020365L (no)	1999-07-28	2002-01-23	Oligonukleotider for inhibiering av ekspresjonen av humant eg5

Country Status (26)

Country	Link
US (1)	US6472521B1 (no)
EP (1)	EP1204742A2 (no)
JP (1)	JP2003505080A (no)
KR (1)	KR20020033744A (no)
CN (1)	CN1165617C (no)
AR (1)	AR024953A1 (no)
AU (1)	AU6568200A (no)
BR (1)	BR0013180A (no)
CA (1)	CA2380192A1 (no)
CZ (1)	CZ2002324A3 (no)
DE (1)	DE19935303A1 (no)
EE (1)	EE200200044A (no)
HK (1)	HK1048337B (no)
HR (1)	HRP20020075A2 (no)
HU (1)	HUP0202794A3 (no)
IL (1)	IL147541A0 (no)
MX (1)	MXPA02000817A (no)
NO (1)	NO20020365L (no)
NZ (1)	NZ516839A (no)
PL (1)	PL353733A1 (no)
RU (1)	RU2249458C2 (no)
SK (1)	SK1162002A3 (no)
TR (1)	TR200200201T2 (no)
WO (1)	WO2001007602A2 (no)
YU (1)	YU91901A (no)
ZA (1)	ZA200200655B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6617115B1 (en) *	1999-10-27	2003-09-09	Cytokinetics, Inc.	Methods of screening for modulators of cell proliferation
US6440686B1 (en)	2000-06-15	2002-08-27	Cytokinetics, Inc.	Methods for screening and therapeutic applications of kinesin modulators
US6809102B2 (en)	2001-03-29	2004-10-26	Bristol-Myers Squibb Company	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en)	2001-03-29	2005-05-31	Bristol-Myers Squibb Company	Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US20040009156A1 (en) *	2001-10-12	2004-01-15	Christoph Reinhard	Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) *	2002-05-23	2007-01-16	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US7199107B2 (en) *	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
JP2006521794A (ja) *	2003-02-14	2006-09-28	スミスクライン・ビーチャム・コーポレイション	Ｋｓｐ発現と相関関係にある示差発現核酸
US7662581B1 (en)	2003-12-18	2010-02-16	Novartis Vaccines And Diagnostics, Inc.	Eg5 co-crystals
ES2360073T3 (es) *	2004-03-23	2011-05-31	Oncotherapy Science, Inc.	Método para diagnosticar cáncer de pulmón de células no pequeñas.
US7700567B2 (en) *	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
KR101362681B1 (ko) *	2006-03-31	2014-02-13	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법
RU2464030C2 (ru) *	2006-05-26	2012-10-20	Регадо Байосайенсиз, Инк.	Введение противосвертывающей системы reg1
US20090048193A1 (en) *	2006-05-26	2009-02-19	Rusconi Christopher P	Administration of the REG1 anticoagulation system
WO2009060281A2 (en) *	2007-11-06	2009-05-14	Coley Pharmaceutical Gmbh	Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
DE102010007562A1 (de) *	2010-02-10	2011-08-11	sterna biologicals GmbH & Co KG, 35043	Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
UA116528C2 (uk)	2011-08-30	2018-04-10	Астекс Фармасьютікалз, Інк.	Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
US9498540B2 (en)	2013-03-15	2016-11-22	Novartis Ag	Cell proliferation inhibitors and conjugates thereof
BR112015027322A8 (pt)	2013-05-01	2018-01-02	Isis Pharmaceuticals Inc	Compostos antissenso conjugados e sua utilização
CA2921839A1 (en) *	2013-08-28	2015-03-05	Ionis Pharmaceuticals, Inc.	Modulation of prekallikrein (pkk) expression
BR112016007751A2 (pt) *	2013-10-11	2017-09-12	Ionis Pharmaceuticals Inc	composições para modulação de expressão de c9orf72
MX380866B (es) *	2014-05-01	2025-03-12	Ionis Pharmaceuticals Inc	Composiciones y métodos para modular la expresión del factor b del complemento.
CN108024535A (zh)	2015-07-02	2018-05-11	大塚制药株式会社	冻干药物组合物
MX2020001233A (es)	2017-08-03	2020-07-20	Otsuka Pharma Co Ltd	Compuesto farmaceutico y metodos de purificacion del mismo.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0171066A3 (de)	1984-08-09	1989-02-01	Siemens Aktiengesellschaft	Verfahren und Schaltungsanordnung zum Adressieren von Signalabgabe-/Signalaufnahmeeinrichtungen von einer zentralen Verarbeitungseinrichtung her
DK0464638T3 (da)	1990-07-02	1997-10-13	Hoechst Ag	Oligonukleotidanaloge med terminale 3-3- eller 5-5-internukleotidbindinger.
IL104461A (en)	1992-01-22	2001-05-20	Hoechst Ag	Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them
US6033909A (en)	1992-01-22	2000-03-07	Hoechst Aktiengesellschaft	Oligonucleotide analogs, their preparation and use
ATE151773T1 (de)	1992-09-24	1997-05-15	Hoechst Ag	Oligoribonucleotid- und ribozym-analoga mit terminalen 3'-3'-bzw.5'-5'-verknüpfungen
GB9311113D0 (en) *	1993-05-28	1993-07-14	Medical Res Council	Probes
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5801154A (en) *	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
DE4408528A1 (de)	1994-03-14	1995-09-28	Hoechst Ag	Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
DE4415370A1 (de)	1994-05-02	1995-11-09	Hoechst Ag	Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de)	1994-11-04	1996-05-09	Hoechst Ag	Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de)	1995-01-31	1996-08-01	Hoechst Ag	G-Cap Stabilisierte Oligonucleotide
DE59607750D1 (de)	1995-03-13	2001-10-31	Aventis Pharma Gmbh	Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US6309821B1 (en) *	1996-05-16	2001-10-30	Incyte Genomics, Inc.	DNA encoding a PAC10 human homolog
WO1999005278A1 (en) *	1997-07-23	1999-02-04	Brigham & Women's Hospital, Inc.	Lens epithelial cell derived growth factor
JP2002519000A (ja) *	1998-01-28	2002-07-02	カイロンコーポレイション	ヒト遺伝子および遺伝子発現産物ｉｉ

1999
- 1999-07-28 DE DE19935303A patent/DE19935303A1/de not_active Withdrawn
2000
- 2000-07-21 KR KR1020027001188A patent/KR20020033744A/ko not_active Ceased
- 2000-07-21 RU RU2002105021/15A patent/RU2249458C2/ru not_active IP Right Cessation
- 2000-07-21 YU YU91901A patent/YU91901A/sh unknown
- 2000-07-21 TR TR2002/00201T patent/TR200200201T2/xx unknown
- 2000-07-21 BR BR0013180-6A patent/BR0013180A/pt not_active IP Right Cessation
- 2000-07-21 HK HK03100581.2A patent/HK1048337B/zh not_active IP Right Cessation
- 2000-07-21 JP JP2001512871A patent/JP2003505080A/ja not_active Withdrawn
- 2000-07-21 HU HU0202794A patent/HUP0202794A3/hu unknown
- 2000-07-21 SK SK116-2002A patent/SK1162002A3/sk unknown
- 2000-07-21 AU AU65682/00A patent/AU6568200A/en not_active Abandoned
- 2000-07-21 HR HR20020075A patent/HRP20020075A2/hr not_active Application Discontinuation
- 2000-07-21 CA CA002380192A patent/CA2380192A1/en not_active Abandoned
- 2000-07-21 CZ CZ2002324A patent/CZ2002324A3/cs unknown
- 2000-07-21 IL IL14754100A patent/IL147541A0/xx unknown
- 2000-07-21 MX MXPA02000817A patent/MXPA02000817A/es unknown
- 2000-07-21 NZ NZ516839A patent/NZ516839A/en unknown
- 2000-07-21 EP EP00953119A patent/EP1204742A2/de not_active Withdrawn
- 2000-07-21 WO PCT/EP2000/007345 patent/WO2001007602A2/de not_active Ceased
- 2000-07-21 EE EEP200200044A patent/EE200200044A/xx unknown
- 2000-07-21 PL PL00353733A patent/PL353733A1/xx not_active Application Discontinuation
- 2000-07-21 CN CNB008108293A patent/CN1165617C/zh not_active Expired - Fee Related
- 2000-07-26 AR ARP000103872A patent/AR024953A1/es unknown
- 2000-07-27 US US09/627,122 patent/US6472521B1/en not_active Expired - Fee Related
2002
- 2002-01-23 NO NO20020365A patent/NO20020365L/no unknown
- 2002-01-24 ZA ZA200200655A patent/ZA200200655B/en unknown

Also Published As

Publication number	Publication date
CN1165617C (zh)	2004-09-08
JP2003505080A (ja)	2003-02-12
MXPA02000817A (es)	2002-07-30
KR20020033744A (ko)	2002-05-07
NO20020365D0 (no)	2002-01-23
HRP20020075A2 (en)	2005-10-31
EE200200044A (et)	2003-06-16
TR200200201T2 (tr)	2002-05-21
ZA200200655B (en)	2003-09-23
AU6568200A (en)	2001-02-13
RU2249458C2 (ru)	2005-04-10
CA2380192A1 (en)	2001-02-01
CZ2002324A3 (cs)	2002-05-15
WO2001007602A3 (de)	2001-05-17
NZ516839A (en)	2004-04-30
YU91901A (sh)	2003-02-28
HK1048337A1 (en)	2003-03-28
CN1367828A (zh)	2002-09-04
EP1204742A2 (de)	2002-05-15
BR0013180A (pt)	2002-04-09
US6472521B1 (en)	2002-10-29
SK1162002A3 (en)	2002-06-04
DE19935303A1 (de)	2001-02-08
HUP0202794A2 (en)	2003-03-28
HK1048337B (zh)	2005-02-25
AR024953A1 (es)	2002-10-30
HUP0202794A3 (en)	2006-03-28
WO2001007602A2 (de)	2001-02-01
PL353733A1 (en)	2003-12-01
IL147541A0 (en)	2002-08-14

Publication	Publication Date	Title
NO20020365L (no)	2002-03-25	Oligonukleotider for inhibiering av ekspresjonen av humant eg5
NO20013380D0 (no)	2001-07-06	2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no)	2001-07-06	2-oksybenzoksazinonderivater for behandling av fedme
NO20013369D0 (no)	2001-07-06	Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20014379L (no)	2001-11-07	Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20021400D0 (no)	2002-03-20	Terapeutiske konazolinderivater
DE60031417D1 (de)	2006-11-30	Kosmetiktuch
ATE392890T1 (de)	2008-05-15	Hydrogel-gesteuerte dosierungsform
NO20024775D0 (no)	2002-10-03	Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20013965L (no)	2001-10-17	Aktivering av nedihullsanordninger
NO20016151D0 (no)	2001-12-17	Fremstilling av substituerte piperidin-4-oner
NO20024777D0 (no)	2002-10-03	Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776L (no)	2002-12-03	Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
DE60029273D1 (de)	2006-08-24	Titan-Tinoxidfilme
NO20020784D0 (no)	2002-02-18	Medikament for behandling av brudd
PT1178984E (pt)	2003-06-30	Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20003799L (no)	2001-01-29	Innkorporering av kolesterol senkende midler i konfekt- dosisformer
NO20012612L (no)	2001-07-17	Isonipecotamider for behandlingen av integrin-formidlede sykdommer
PT1200447E (pt)	2004-02-27	Oxazinocarbazoles para o tratamento de doencas do snc
NO20014845D0 (no)	2001-10-05	Anvendelse av arylalkanoylpyridaziner
NO20014026D0 (no)	2001-08-17	Krampestillende derivater til behandling av betydelig skjelving
NO20020328D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20005856D0 (no)	2000-11-20	Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
NO20020327D0 (no)	2002-01-22	Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol